Should You Buy Nuveen New York Quality Municipal Income Fund (NAN) Today? Analysis, Price Targets, and 2026 Outlook.
No data
No data
Growth
Profitability
Efficiency
Wall Street analysts forecast NAN stock price to rise
0 Analyst Rating
0
Wall Street analysts forecast NAN stock price to rise
0 Buy
0 Hold
0 Sell
0
Current: 11.465
Low
0
Averages
0
High
0
0
Current: 11.465
Low
0
Averages
0
High
0
RBC Capital
Underperform -> Sector Perform
upgrade
$4
AI Analysis
2026-01-19
Reason
RBC Capital
Price Target
$4
AI Analysis
2026-01-19
upgrade
Underperform -> Sector Perform
Reason
RBC Capital upgraded Nanosonics to Sector Perform from Underperform with an unchanged price target of A$4. The firm views the shares as fairly valued now that earnings estimates have bene reset.
Goldman Sachs
Neutral
maintain
$30 -> $37
2025-12-02
Reason
Goldman Sachs
Price Target
$30 -> $37
2025-12-02
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on NewAmsterdam Pharma to $37 from $30 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NAN
